Rep. Gilbert Ray Cisneros, Jr. Buys Shares of Insulet Corporation (NASDAQ:PODD)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Insulet Corporation (NASDAQ:PODD). In a filing disclosed on September 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in Insulet stock on August 18th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 8/28/2026.
• Purchased $15,001 – $50,000 in shares of Quanta Services (NYSE:PWR) on 8/27/2026.
• Purchased $15,001 – $50,000 in shares of Eaton (NYSE:ETN) on 8/27/2026.
• Sold $15,001 – $50,000 in shares of NIKE (NYSE:NKE) on 8/27/2026.
• Sold $1,001 – $15,000 in shares of Phreesia (NYSE:PHR) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of Wheaton Precious Metals (NYSE:WPM) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of Walmart (NASDAQ:WMT) on 8/26/2026.
• Purchased $1,001 – $15,000 in shares of The Goldman Sachs Group (NYSE:GS) on 8/26/2026.
• Sold $15,001 – $50,000 in shares of Lamar Advertising (NASDAQ:LAMR) on 8/25/2026.
• Sold $1,001 – $15,000 in shares of Phreesia (NYSE:PHR) on 8/25/2026.

Insulet Stock Performance

Shares of NASDAQ PODD traded down $2.72 during trading hours on Friday, hitting $131.96. 1,747,929 shares of the stock were exchanged, compared to its average volume of 1,624,980. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.48 and a quick ratio of 1.83. The company’s 50 day moving average is $152.36 and its 200 day moving average is $173.92. The firm has a market capitalization of $9.15 billion, a P/E ratio of 24.67, a P/E/G ratio of 1.06 and a beta of 1.08. Insulet Corporation has a one year low of $126.40 and a one year high of $354.88.

Insulet (NASDAQ:PODD) last announced its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, topping the consensus estimate of $1.47 by $0.19. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The firm had revenue of $801.70 million for the quarter, compared to the consensus estimate of $787.39 million. During the same quarter last year, the firm posted $1.17 EPS. The business’s quarterly revenue was up 23.5% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.460- EPS. On average, research analysts expect that Insulet Corporation will post 6.51 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. California State Teachers Retirement System raised its position in Insulet by 13,901.9% in the second quarter. California State Teachers Retirement System now owns 14,562,256 shares of the medical instruments supplier’s stock worth $2,217,103,000 after purchasing an additional 14,458,254 shares in the last quarter. BlackRock Inc. acquired a new stake in Insulet during the second quarter valued at approximately $1,018,582,000. Norges Bank bought a new stake in shares of Insulet in the 4th quarter valued at approximately $300,794,000. Arrowstreet Capital Limited Partnership raised its holdings in shares of Insulet by 462.7% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock worth $258,088,000 after buying an additional 1,011,369 shares in the last quarter. Finally, Man Group plc bought a new position in shares of Insulet during the 2nd quarter worth approximately $78,746,000.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on PODD shares. BTIG Research cut Insulet from a “buy” rating to a “neutral” rating in a research report on Thursday, August 6th. Wells Fargo & Company lowered Insulet from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $255.00 to $144.00 in a report on Wednesday, August 5th. Stifel Nicolaus cut their price target on Insulet from $225.00 to $180.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Evercore set a $180.00 price target on Insulet in a report on Monday, July 6th. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of Insulet in a research note on Tuesday, June 23rd. They issued a “buy” rating and a $190.00 price objective on the stock. Fourteen equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $195.40.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Insulet Company Profile

Insulet Corporation is a medical device company that develops, manufactures and sells wearable insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s principal product platform is Omnipod, a tubeless, wearable insulin pump system. Omnipod products include the disposable, wearable Pod and related management and smartphone-based technologies.